Assisted Reproductive Technology Companies

The assisted reproductive technology market is projected to reach USD 6.02 Billion by 2030 from USD 4.29 Billion in 2025 at a CAGR of 7.0% during the forecast period.

Rising rates of infertility caused due to postponed birth, changed ways of living, and growing familiarity with fertility technology are fueling the market of assisted reproductive technologies (ARTs).  Growth is taking place due to advancement in medical technologies, rising procedure success rates in procedures such as in-vitro fertilization (IVF), and subsidies from governments towards the sector. Conversely, health risks associated with ART therapy, ethical and legal issues, and the exorbitant cost of treatment are limiting factors.  The psychological and physical burden of ART and the unavailability of reproductive therapies in developing countries further limit market growth.  In spite of these issues, research and developmet continues to make ART solutions better and cheaper.

To know about the assumptions considered for the study download the pdf brochure

In this report, the assisted reproductive technologies market has been segmented on the basis of technology, type, patient type, care settings and region.

Prominent players in this market include CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US), among others.

In June 2024, CooperSurgical Inc. (US) acquired ZyMot Fertility, a subsidiary of DxNow, Inc. The sperm separation device of ZyMot Fertility will add to the CooperSurgical Inc. portfolio of ART products and services.

In December, Cook Medical Inc. (US) collaborated with Bedal International, a company known for its catheter securement devices, which are sold under the brand FlexGRIP.

COOPERSURGICAL INC.

CooperSurgical Inc. is the global healthcare leader in providing innovative medical devices and solutions for women's health and fertility. It is a part of a larger healthcare company, The Cooper Companies. This business unit markets its products under various brand names, such as ORIGIO (IVF products), Reprogenetics (genetic testing solutions), and LifeGlobal (media products as well as IVF laboratory air filtration products). CooperSurgical Inc. operates in over 100 countries worldwide. This vast geographic reach makes them a major player in the global healthcare market.

FUJIFILM IRVINE SCIENTIFIC

FUJIFILM Irvine Scientific provides advanced culture media, embryo transfer solutions, and diagnostic tools to enhance the success rates of IVF and embryo cryopreservation. Its strategies focus on continuous innovation and research to improve clinical outcomes, global expansion to meet the growing demand in emerging markets, and forming strategic partnerships with fertility clinics and research institutions. By investing in acquisitions and maintaining a customer-centric approach, FUJIFILM Irvine Scientific strengthens its position as a key player in the ART sector, offering solutions to support fertility treatments and improve patient outcomes worldwide.

VITROLIFE

Vitrolife develops, manufactures, and markets instruments, systems, and cultivation media related to assisted reproduction techniques. The company offers various products for procedures, such as sperm preparation, oocyte retrieval, conventional IVF, ICSI, embryo culture, embryo transfer, vitrification, and slow freezing. Vitrolife is one of the first companies to provide high-standard, ready-to-use culture media to IVF clinics. The fertility segment develops, produces, and markets nutrient solutions (media), products for cryopreservation, advanced disposable instruments such as needles and pipettes, and offers time-lapse technology for assisted reproduction.

Market Ranking:

The assisted reproductive technology market is competitive, with five main players collectively holding 33-40% of the total market share. The segmental revenue analysis of key players in the ART market indicates CooperSurgical, Inc. (US) accounted for the largest share of the market. The segments that offer ART instruments contribute a major share of the overall revenue of these key players. The revenue fluctuations in the ART (Assisted Reproductive Technology) market can be attributed to several key factors. The significant revenue boost in 2021 was likely driven by increased demand for fertility treatments post-COVID-19 pandemic, as delayed procedures resumed and investments in ART technologies surged. Advancements in reproductive medicine, growing awareness, and expanding insurance coverage contributed to higher revenues. However, the decline observed from 2022 onward may be due to market saturation, economic slowdowns, shifting consumer priorities, and regulatory challenges affecting ART accessibility and affordability. Furthermore, competitive pressures and pricing adjustments by key players may have contributed to revenue normalization after the peak demand in 2021.

Related Reports:

Assisted Reproductive Technology Market by Technology (In Vitro Fertilization, Artificial Insemination), Type (Instruments (Incubators), Media (Cryopreservation), Supplements, Consumables), Patient Type (Male, Female), End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com